The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.
Key Implementation Steps for Stakeholders
- Procurement Volume Verification:
Healthcare institutions and selected suppliers must log into the Guangdong Bidding and Procurement Subsystem (via CA authentication) to review assigned procurement quotas under “Drug Transactions > Catalog Management > Hospital Agreement Volume.” - Distribution Network Setup:
Manufacturers of winning/volume-limited products (listed in the attached catalog) are required to establish配送 relationships through the subsystem’s “Drug Transactions > Distribution Management (Production)” module. Operational guidelines are available on the platform’s “Member Services > Guides” section. - Compliance and Supply Assurance:
- Manufacturers bear primary responsibility for quality control and delivery reliability, ensuring coverage across all participating medical institutions.
- Proactive inventory management is urged to prevent supply disruptions.
Strategic Implications for the Pharmaceutical Industry
- Cost Efficiency: The VBP model reinforces price negotiation, likely pressuring margins but expanding market access for compliant firms.
- Operational Agility: Enhanced distribution requirements demand robust logistics partnerships and real-time monitoring systems.
- Quality Compliance: Stricter oversight underscores the need for GMP adherence and post-market surveillance.
Contact Information
- Online support via the Guangdong Drug Trading Center’s official website.
- Hotline: 0086-20-29195621 / 0086-20-38036197 (Weekdays: 8:30–12:00, 14:00–17:30).-Fineline Info & Tech
Leave a Reply